What is the rate of loss of response to infliximab therapy in crohn's disease

American Journal of Gastroenterology

Volumn 104, Issue 9, 2009, Pages 2353-2354

  Chao, Jingdong ^a   Mulani, Parvez ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

CROHN DISEASE; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; CROHN DISEASE; DRUG TOLERANCE; HUMANS;

EID: 69949149434     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.375     Document Type: Letter

References (10)

1. Gisbert JP, Pan é s J. Loss of response and requirement of infl iximab dose intensifi cation in Crohn's disease: A review. Am J Gastroenterol 2009; 104: 760-7.
2. Regueiro M, Siemanowski B, Kip KE et al. Infliximab dose intensifi cation in Crohn's disease. Infl amm Bowel Dis 2007; 13: 1093-9
3. Schnitzler F, Fidder H, Ferrante M et al. Flexibility in interval and dosing of infl iximab enables maintained response of patients with Crohn's disease. Gastroenterology 2008; 134 (Suppl 1):A658.
4. Gonzaga JE, Issa M, Skaros S et al. Durability of infl iximab in Crohn's disease patients treated with maintenance infusions beyond one year. Gastroenterology 2008; 134 (Suppl 1):A665.
5. Rudolph SJ, Weinberg DI, McCabe RP. Longterm durability of Crohn's disease treatment with infl iximab. Dig Dis Sci 2008; 53: 1033-41.
6. Sands BE, Anderson FH, Bernstein CN et al. Infl iximab maintenance therapy for fi stulizing Crohn's disease. N Eng J Med 2004; 350: 876-85.
7. Hommes DW, van de Heisteeg BH, van der Spek M et al. Infl iximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Infl amm Bowel Dis 2002; 8: 81-6.
8. Teshima CW, Th ompson AF, Dhanoa LS et al. Concomitant use of immunosuppressive therapy in an outpatient IBD subspecialty clinic results in rates of response higher than those seen in the infl iximab randomized trials. Gastroenterology 2008; 134 (Suppl 1):A663.
9. Kaplan GG, Hur C, Korzenik J et al. Infl iximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a costeff ectiveness analysis. Aliment Pharmacol Th er 2007; 26: 1509-2.
10. Mulani P, Chao J. Infl iximab vs. adalimumab for Crohn's disease. Aliment Pharmacol Th er 2008; 28: 1265-6.